Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Biomarin Pharmaceutical Q4 Sales $537.54M Beat $536.97M Estimate

Biomarin Pharmaceutical (NASDAQ:BMRN) reported quarterly sales of $537.54 million which beat the analyst consensus estimate of $536.97 million by 0.11 percent. This is a 19.50 percent increase over sales of $449.81
byBenzinga Newsdesk
February 27, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Biomarin Pharmaceutical (NASDAQ:BMRN) reported quarterly sales of $537.54 million which beat the analyst consensus estimate of $536.97 million by 0.11 percent. This is a 19.50 percent increase over sales of $449.81 million the same period last year.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

EXCLUSIVE: Alzamend Neuro Submits IND For Phase IIA Trial Of Next-Gen Lithium Candidate In Major Depressive Disorder

By Akanksha Bakshi
October 23, 7:31 AM
Alzamend Neuro Inc (NASDAQ: ALZN) has submitted an investigational new drug (IND) application to the FDA to initiate AL001-MDD01, a Phase IIA plasma/brain pharmacokinetics clinical study of AL001 for adjunctive treatment of patients with major depressive disorder (MDD).

ALZN